- Reports: ESI may start 'price war' over new hepatitis C drugs
- Could ESI block Sovaldi from its formulary?
- Walgreens expands access to Walgreens Connected Care hepatitis C program
- Experimental AbbVie treatment regimen for hepatitis C produces 96% cure rate
- Newly approved hepatitis C treatment by Gilead Sciences said to offer major advance in treatment
FLINT, Mich. — An executive from Diplomat Specialty Pharmacy recently participated in a program on hepatitis C therapy, the company said.
Diplomat said VP clinical services Gary Rice participated in the "think tank" program, "The New Paradigm of HCV Therapy - Integration of Oral Therapies into Best Practices," at the Harvard Medical School in Boston last week. The goal of the meeting was to provide a forum for exchanging the latest knowledge and opinions on the optimal diagnosis and management of people with chronic hepatitis C, with a focus on current and experimental therapies, access to therapy, diagnosis and testing, patient care management and patient advocacy.
"Diplomat Specialty Pharmacy strives to provide the best care, resources and current information to our patients," Rice said. "To have the opportunity to participate in this Harvard think tank and meet and discuss optimal hepatitis C treatments with some of the best medical minds in the country was a privilege and an invaluable return for our patients."